VIVRO

Vivro Financial Services Private Limited

Regd. Office :

Vivro House, 11, Shashi Colony, Opp. Suvidha Shopping Center,

Paldi, Ahmedabad, Gujarat, India - 380 007

Tel.: +91 (79) 4040 4242

www.vivro.net

Date: May 25, 2026

To,

BSE Limited

Phiroze Jejeebhoy Towers,

Dalal Street,

Mumbai – 400 001

Sub: Detailed Public Statement for the proposed Open Offer for acquisition of Equity Shares from the Public Shareholders of Lippi Systems Limited (“Target Company”) by Vinesh Shivji Dholu (“Acquirer 1”), Jagdish Shivji Dholu (“Acquirer 2”), Shivji Karamshi Dholu (“Acquirer 3”), Jagruti Vinesh Dholu (“Acquirer 4”), Parul Jagdish Dholu (“Acquirer 5”) pursuant to and in compliance with the requirements of the SEBI (SAST) Regulations (the “Open Offer” or “Offer”).

Dear Sir / Madam,

With reference to the captioned subject, enclosed herewith is the Detailed Public Statement (‘DPS’), published in compliance with Regulation 13(4) and 14(3) of the SEBI SAST Regulations today i.e. Monday, May 25, 2026, in the following newspaper:

Newspaper	Language	Edition
Financial Express	English	All
Jansatta	Hindi	All
Navshakti	Marathi	Mumbai
Financial Express	Gujarati (Regional)	Ahmedabad

We have hereby attached e-clippings of the newspaper for your perusal. We request you to disseminate the said information on your website.

Capitalised terms used in this letter unless defined herein shall have the same meanings as ascribed to them in the enclosed DPS.

Yours Faithfully,

For, Vivro Financial Services Private Limited

Jayesh Vithlani

Sr. Vice President Capital Markets

Encl.: Detailed Public Statement.

CIN - U67120GJ1996PTC029182, Merchant Banker Sebi. Reg. No. INM000010122, AIBI Reg. No. AIBI/086

LIPPI SYSTEMS LIMITED

Registered Office: LEY & SOL, 9th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th

Registered Office: LEY & SOL, 9th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10

Registered Office: LEY & SOL, 9th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10th Floor, 10

Registered Office: LEY & SOL, 9th Floor, 10th Floor, 10th Floor, 10th Floor, 10

Registered Office: LEY & SOL, 9th Floor, 10th Floor, 10th Floor, 10

Registered Office: LEY & SOL, 9th Floor, 10th Floor, 10

^{}[]

Sc No.	Particulars	Price (in € per Equity Share)
A	Highest negotiated price under the GPA & SGA.	56.84
B	The volume-weighted average price paid or payable for acquisitions by the Acquirers / PAC, during 12 weeks immediately preceding the date of the PA.	N.A.
C	Highest price paid or payable for any acquisition by the Acquirers / PAC, during 18 weeks immediately preceding the date of the PA.	N.A.
D	The volume-weighted average market price of shares for a period of 60 trading days immediately preceding the date of PA as traded on the stock exchange where the maximum volume of trading in the shares of the Target Company are recorded during such period.	48.64
E	The price determined being into account valuation parameters.	N.A.
F	the per share value computed under sub-regulation (5), if applicable	Not Applicable1)

Note 1. Not Applicable since the acquisition is not an indirect acquisition.

The fair value of Equity Shares of the Target Company is $166.84/-$ (Purpose Fifty Six and Paisa Eighty Four Only) as certified by CA Cliving Naval training (CAI Membership No. 151024, Partner of S.K. Patin & Co. (PAN: 112947W)) who certify the leasing UDIN 2013/1033442/AM/2017 dated May 18, 2020, having its office at 401-404, Vraj Valencia, Behind Mahestra Show Room for Sola Overbridge, S. G. Highway, Sola, Ahmedabad-380066, Gujarat, Email ID: [email protected]

In view of the parameters considered and presented in the aforesaid table, the minimum offer price per Equity Share under Regulation 8(2) of the SEBI (SAST) Regulations is the highest of item numbers A to F above i.e., € 90.84 per Equity Share. Accordingly, the Offer Price of € 90.84/- (Purpose Fifty Six and Paisa Eighty Four Only) is justified in terms of the SEBI (SAST) Regulations.

Since the date of the PA and as on the date of the GPA, there have been no corporate actions in the Target Company warranting adjustment of relevant price parameters under Regulation A(4) of the SEBI (SAST) Regulations. The Offer Price may be adjusted in the event of any corporate action like bonus, rights issues, stock split, consolidation, etc. where the record date for effecting such corporate actions falls prior to 2 Working Days before the commencement of the Tendering Period of the Offer, in accordance with Regulation A(4) of the SEBI (SAST) Regulations.

In the event of further acquisition of Equity Shares of the Target Company by the Acquirers during the Offer Period, whether by subscription or purchase, at a price higher than the Offer Price, then the Offer Price will be revised by the Acquirer. The value for more than the highest price paid for such acquisition in terms of Regulation A(4) of the SEBI (SAST) Regulations. However, Acquirers shall not acquire any Equity Shares of the Target Company after the third Working Days prior to the commencement of the Tendering Period and until the expiry of the Tendering Period.

If the Acquirers acquire Equity Shares of the Target Company during the period of twenty-six weeks after the Tendering Period at a price higher than the Offer Price, then the Acquirers shall pay for difference between the highest acquisition price and the Offer Price. In all Public Shareholders whose Equity Shares have been accepted in the Offer within 60 (only) days from the date of such acquisition. However, no such difference shall be paid in the event that such acquisition is made under another open offer under the SEBI (SAST) Regulations, or pursuant to SEBI Debating Regulations, or open market purchases made in the ordinary course on the Stock Exchange, not being negotiated acquisition of Equity Shares of the Target Company in any form.

The Acquirers are permitted to revise the Offer Price upward at any time up to 1 (one) Working Day prior to the commencement of the Tendering Period of the Offer in accordance with Regulation 16(4) of the SEBI (SAST) Regulations. In the event of such upward revision in the Offer Price, the Acquirers shall make further deposits into the Escrow Account, make a public announcement in the same newspapers where the original OPS has been published and simultaneously inform SEBI, BSE and Target Company at its registered office of such revision.
As no date, there is no revision in Offer Price or Offer Size. In case of any revision in the Offer Price or Offer Size, the Acquirers shall comply with Regulation 16 of SEBI (SAST) Regulations and all other applicable provisions of SEBI (SAST) Regulations which are required to be fulfilled for the said revision in the Offer Price or Offer Size.

1. FINANCIAL ARRANGEMENTS:

The total fixed requirement for implementation of the Open Offer (assuming full acceptance) i.e. for the acquisition of up to $3,92,231$ (The ty Three Lakh Eighty Two Thousand Two Hundred Thirty-One) Equity Shares from all the Public Shareholders of the Target Company at an Offer Price of $9,64/-$ (Purpose Fifty Six and Paisa Eighty Four Only) per Equity Share is of € 15,22.46,010.04/- (Purpose Nineteen Crore Twenty Two Lakh Forty Six Thousand Two and Paisa Four Only) ("Maximum Consideration").

In accordance with Regulation 17 of SEBI (SAST) Regulations, the Acquirers and Manager to the Offer have entered into an escrow agreement with HDFC Bank Limited ("Eazme Agent") on May 18, 2020 ("Eazme Agreement") and have opened an escrow account under the name and style of Vinech Shoa Chroo-47 ("Escrow Account") with the Escrow Agent. In accordance with the requirements of Regulation 17 of the SEBI (SAST) Regulations, the Acquirers have deposited in cash, through banking channels, an aggregate of 4,81,00,000/- (Purpose Four Crore Eighty One Lakh Only) ("Eazme Amount") in the Escrow Account which is more than 25% of the total consideration payable in the Offer, assuming full acceptance. In terms of the Escrow Agreement, the Manager to the Offer has been authorized by the Acquirers to operate the Escrow Account in accordance with the SEBI (SAST) Regulations. The deposit of the Escrow Amount has been confirmed by the Escrow Agent by way of a confirmation letter dated May 22, 2020.

The Acquirers have authorized the Manager to the Offer to operate the Escrow Account and realize the value of the Escrow Amount in terms of the SEBI (SAST) Regulations.

The Acquirers have confirmed that they have adequate financial resources to meet the obligations under the Open Offer and have made firm financial arrangements for fulfilling the payment obligations under this Open Offer in terms of Regulation 25(1) of the SEBI (SAST) Regulations and the Acquirers are able to implement this Open Offer.

After considering the aforementioned, CA Cliving Naval training (CAI Membership No. 151024, Partner of S.K. Patin & Co., PAN: 112947W) who certify the leasing UDR 2013/1024242/AM/2013 dated May 21, 2020, having office at 401-404, Vraj Valencia, Behind Mahestra Show Room for Sola Overbridge, S. G. Highway, Sola, Ahmedabad-380066, Gujarat, Email ID: [email protected] have certified that the Acquirer has not made firm financial arrangements to make any financial obligations under the Open Offer.

Based on the above and in the light of the escrow arrangements, the Manager to the Offer is satisfied (up about the adequacy of revision) in the case of the financial requirements for the Open Offer and the ability of the Acquirers to implement the Open Offer in accordance with the SEBI (SAST) Regulations, (b) that firm arrangements for payment through verifiable means have been put in place by the Acquirers to fulfill their obligations in relation to the Offer in accordance with the SEBI (SAST) Regulations.

In case of passed revision in the Offer Price and/or the Offer Size, the corresponding increase to the Escrow Amount as mentioned above shall be made by the Acquirers to ensure compliance with Regulation 16(5) of the SEBI (SAST) Regulations.

II. STATUTORY AND OTHER APPROVALS:

As on the date of the GPC, there are no statutory or other approvals required to acquire the Offer Shares that may be validly tendered pursuant to this Offer and/or to complete the Underlying Transaction except approval from BSE Limited and shareholders for Preferential Issue of warrants to the Acquirers. However, if any statutory or other approval(s) becomes applicable prior to the completion of the Offer, the Offer would also be subject to such statutory or other approval(s) being obtained and the Acquirers shall make necessary applications for such approval.

If the holders of the Equity Shares who are not persons resident in India (including NRA, CEOs and FAs) had required any approvals (including from the ABI, the PPR or any other regulatory body) in respect of the Equity Shares held by them, they will be required to submit such previous approvals, that they would have obtained for holding the Equity Shares, to tender the Equity Shares held by them in this Offer, along with the other documents required to be tendered to accept the Offer, in the event such approvals are not submitted, the Acquirers must be the right to reject such Equity Shares tendered in this Offer.

In terms of Regulation 23 of the SEBI (SAST) Regulations, the Acquirers shall have the right to withdraw the Open Offer (a) in the event that any of statutory or other approvals specified in this Part VI (Statutory and Other Approvals) or those which become applicable prior to completion of the Open Offer are finally refused; or (b) if any of the conditions under the GPA, as set out in para 4 of Part II (Background of the Offer specified in this OPS are not satisfied for reasons outside the reasonable control of the Acquirer), in the event of such a withdrawal of the Open Offer, the Acquirers (through the Manager) shall, within 2 Working Days of such withdrawal, make an announcement of such withdrawal stating the grounds for the withdrawal in accordance with Regulation 23(2) of the SEBI (SAST) Regulations.

Subject to the receipt of the statutory and other approvals, if any, the Acquirers shall complete payment of consideration within 10 (ten) Working Days from the closure of the Tendering Period to those Public Shareholders whose documents are found valid and in order and are approved for acquisition by the Acquirers.

Where any statutory or other approval extends to some but not all of the Public Shareholders, the Acquirers shall have the option to make payment to such Public Shareholders in respect of whom no statutory or other approvals are required in order to complete this Open Offer.

In case of delay in receipt of any statutory approval(s) becoming applicable prior to completion of the Offer, SEBI may, if satisfied that the delay in receipt of requisite approval was not due to any willful default or neglect on the part of the Acquirers to diligently pursue the application for the approval, grant extension of time to the Acquirer for payment of consideration to the Public Shareholders of the Target Company who have accepted the Offer within such period, subject to the Acquirers agreeing to pay interest for the delayed period as directed by SEBI in terms of Regulation 16(11) of the SEBI (SAST) Regulations, further, if delay occurs on account of willful default by the Acquirer in obtaining the requisite approvals, Regulation 17(9) of the SEBI (SAST) Regulations will also become applicable and the Escrow Amount lying in the Escrow Account shall become liable to forfeiture.

VII. TENTATIVE SCHEDULE OF ACTIVITY:

Activity	Day and Date
Issue of Public Announcement	Monday, May 18, 2020
Publication of this Detailed Public Statement in newspapers	Monday, May 25, 2020
Last date of filing of draft UIP with SEBI	Tuesday, June 02, 2020
Last date for Public Announcement for competing offer	Tuesday, June 10, 2020
Last date for receipt of comments from SEBI on the draft UIP	Tuesday, June 23, 2020
Identified Date2	Thursday, June 25, 2020
Last date for dispatch of the LOP to the Public Shareholders	Friday, July 5, 2020
Last date of publication by which a committee of independent directors of the Target Company is required to give its recommendation to the Public Shareholders of the Target Company for this Offer	Tuesday, July 7, 2020
Last date for upward revision of the Offer Price and/or the Offer Size	Wednesday, July 8, 2020
Date of publication of opening of Open Offer public announcement in the newspaper in which OPS has been published	Thursday, July 9, 2020
Date of commencement of Tendering Period ("Offer opening Date")	Friday, July 10, 2020
Date of closure of Tendering Period ("Offer Closing Date")	Thursday, July 23, 2020
Last date of communicating of rejections/couplees and payment of consideration for accepted tendered return of unaccepted shares	Thursday, August 6, 2020
Last date for publication of post Open Offer public announcement	Thursday, August 13, 2020
Last date of filing the final report to SEBI	Thursday, August 13, 2020

2) Noted in Table is only for the purpose of determining the names of the Equity Shareholders of the Target Company on the identified Date or completion date given to those who have acquired Equity Shares (including those who have acquired Equity Shares) and who have received the original Acquirer's No. Open Offer. Accidental omission to send the LOP to any person for whom the Offer is made or the non-receipt of delayed receipt of the LOP by any such person will not invalidate the Offer in any way.

The LOP shall be sent through electronic means to those Public Shareholders(s) who have registered their email ids with the depositions / the Company and also will be disapproved through physical mode by registered post / speed post / courier to those Public Shareholders(s) who have not registered their email ids and to those Public Shareholders(s) who hold Equity Shares in physical form. Further, on receipt of request from any Public Shareholders to receive a copy of LOP in physical format, the same shall be provided.

The Public Shareholders may also download the LOP from the SEB's website (www.sebi.gov.in) or obtain a copy of the same from the Registrar to the Offer or providing suitable documentary evidence of holding of the Equity Shares and their folio number, OP identity-client identity, current address and contact details.

The Open Offer will be implemented by the Acquirers through a stock exchange mechanism made available by stock exchange in the form of a separate window ("Acquisition Window"), as provided under the "Check Box" in the "Check Box" column. The LOP will be used to the LOP in the "Check Box" column. The LOP will be used to the LOP in the "Check Box" column.

The LOP shall be the designated stock exchange has been above or below the "Check Box" in the "Check Box" column. Shares in the "Check Box" column will be labeled "B" and "B" in the "Check Box" column.

VIVRO

VIVRO Financial Services Private Limited

Address: Sakar 1, 5th Floor, Ogo Gandhigram Railway Station, Navrangpara, Ahmedabad - 380009

SEBI Reg. No: INZ000206732

Email: [email protected]

Contact Person: Neta Jain

Public Shareholders who desire to handle their Equity Shares within the Open Offer would have to estimate their respective stockholders ("Selling Broker") within the normal trading hours of the secondary shares, as specified in the "Selling Broker" column.
A separate acquisition window will be provided by the BSE to facilitate placing of sell orders. The Selling Broker can enter orders for dematerialized or well-accepted Equity Shares.
The Selling Broker would be required to place an order that on behalf of the Public Shareholders who wish to tender their Equity Shares in the Open Offer unless the acquisition window of the BSE. Before placing the bid, the Public Shareholders' Selling Broker concerned would be required to mark lien on the tendered Equity Shares. Details of such Equity Shares marked as lien in the demal account of the Public Shareholders shall be provided by the depositions to the Clearing Corporation in accordance with SEBI circular no. SEBI-KE-0101025-AC-0141510211615 dated August 13, 2021.
The cumulative quantity tendered shall be displayed on the BSE website (www.tweinda.com) throughout the trading sessions at specific intervals during the Tendering Period.
As per the provisions of Regulation 40(1) of the SEBI (ZDR Regulations and SEBI's prices release dated December 3, 2018, bearing reference no. PA 49/2018, requests for transfer of securities shall not be processed unless the securities are held in dematerialized form with a depositary with effect from April 01, 2019. However, in accordance with the circular issued by SEBI bearing reference number SEBI-KO-072-33421/2001/33551144 dated July 27, 2020, shareholders holding securities in physical form are allowed to tender shares in an Open Offer. Such tendering shall be as per the provisions of the SEBI (SAST) Regulations, Incomlying Public Shareholders holding Equity Shares in physical form as well are eligible to tender their Equity Shares in this Open Offer as per the provisions of the SEBI (SAST) Regulations.
The process of tendering Equity Shares by the Equity Shareholders holding in demal and physical Equity Shares will be repeated by enumerated in the LOP.

IX. THE SETALLED PROCEDURE FOR TENDERING THE EQUITY SHARES IN THE OFFER WILL BE AVAILABLE IN THE LETTER OF OFFER THAT WOULD BE DISPATCHED TO THE EQUITY SHAREHOLDERS OF THE TARGET COMPANY AS ON THE IDENTIFIED DATE.

X. OTHER INFORMATION:

The Acquirers accept full responsibility for the information contained in the PA and this OPS (other than such information as has been obtained from public sources or provided by or relating to and confirmed by the Target Company and/or the Sellers) and under take that they are aware of and will comply with their obligations as laid down in the SEBI (SAST) Regulations in respect of this Open Offer.

The information pertaining to the Target Company contained in the PA or OPS or any other advertisement/publications made in connection with the Open Offer has been compiled from information published or publicly available sources or as provided by the Target Company. The Acquirers and Manager to the Offer have not independently verified such information and do not accept any responsibility with respect to any information provided in the PA or this OPS pertaining to the Target Company.

Pursuant to Regulation 12 of SEBI (SAST) Regulations, the Acquirers and PACs have appointed Vinn Financial Services Private Limited (SEBI Reg. No: MB/IRM000010122), as the Manager to the Open Offer as per the details below.

VIVRO CAREO	Vinn Financial Services Private Limited
	Address: Vinn House, 11 Shacht Colony, Ogo. Suvidha Shopping Centre, Park, Ahmedabad - 380007, Gujarat, India	56-106712002/18IMPT0329182;	Tel No.: 079-49454642; E-mail: [email protected]	Website: www.vinn.net
	SEBI Reg. No. MB/IRM000010122	Contact Person: Shivam Patel

The Acquirers have appointed Cameo Corporate Services Limited as the Registrar to the Offer, as per details below.

CAREO CORPORATE SERVICES LIMITED

Address: Subramanian Building No.1, Clathouse road, 600002 Chennai, Tamil Nadu

CIN: L071207N1998PLC041613 Tel No.: 044-43020700

Email: chyrajitcarmanda.com Website: cambridge.carmanda.com

SEBI Reg. No. 101000003753 Contact Person: K Sreapriya

This OPS and the PA shall also be available on SEBI's website at www.sebi.gov.in and on the website of Manager to the Offer at www.vinn.net

Issued by Manager to the Offer on behalf of the Acquirers:

SsI:	SsI:	SsI:	SsI:
Vinech Shoa (Dnolu)	Jagibsh Shoa (Dnolu)	SsIyaj (Aparesh)	Jagir Vinech Sholu (Parul Jagibsh Sholu)
(Acquirer 1)	(Acquirer 2)	(Dnolu)	(Acquirer 4)
		(Acquirer 5)

Date: May 23, 2020

Place: Ahmedabad

MONDAY, MAY 25, 2018

INTEGRAL PROGRESS COMPUTATION

FINANCIAL EXPRESS

LIPPI SYSTEMS LIMITED

Registered Office: 401 & 402, 1000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000

IN TODAY OF REGULATIONS 1325, 1425 AND 1525 ARE OTHER APPLICABLE REGULATIONS OF THE 22nd International Conference on Financial and Commercial Research on Financial and Commercial Management of the World Bank, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019.

The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019.

The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019.

The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019.

The International Bank of Canada, 2018-2019. The International Bank of Canada, 2018-2019.

The International Bank of Canada, 2018-2019.

WWW.TIHANGALEXPRESS.COM

FINANCIAL EXPRESS

MONDAY, MAY 25, 2026

No.	Particulars	Price or if per Equity Stock
1	Pay from may/should be paid in part or outside for expenditure by the Company (18). Specify all revenue and available ground-truths (including tax, taxes, or other tax) in the tax required for the Acupoint (18). Specify all taxes or more (including tax and other tax) in the tax required for the Acupoint (18).	N.A.
2	The volume-weighted average market price of shares for a period of 30 (melting days immediately preceding the date of 1% as inside) or the stock (concession) where the maximum volume of trading is the lowest of the "Bargyl" (18).	N.A.
3	The price-based percentage of the total value of the "Bargyl" (18) in the tax required for the Acupoint (18).	N.A.
4	For the tax required for the Acupoint (18) the tax is the lowest (18) in the tax required for the Acupoint (18).	N.A.

The tax is the lowest (18) in the tax required for the Acupoint (18) in the tax required for the Acupoint (18) in the tax required for the Acupoint (18) in the tax for the period of 30 (18) years, except for the period of 18 years before the tax is paid.
The tax is the lowest (18) in the tax required for the Acupoint (18) in the tax for the period of 30 (18) years, except for the period of 18 years before the tax is paid.
The tax is the lowest (18) in the tax required for the Acupoint (18) in the tax for the period of 30 (18) years, except for the period of 18 years before the tax is paid.
The tax is the lowest (18) in the tax required for the Acupoint (18) in the tax for the period of 30 (18) years, except for the period of 18 years before the tax is paid.
The tax is the lowest (18) in the tax required for the Acupoint (18) in the tax for the period of 30 (18) years, except for the period of 18 years before the tax is paid.
The tax is the lowest (18) in the tax required for the Acupoint (18) in the tax for the period of 30 (18) years, except for the period of 18 years before the tax is paid.
The tax is the lowest (18) in the tax required for the Acupoint (18) in the tax for the period of 30 (18) years, except for the period of 18 years before the tax is paid.
The tax is the lowest (18) in the tax required for the Acupoint (18) in the tax for the period of 30 (18) years, except for the period of 18 years before the tax is paid.
The tax is the lowest (18) in the tax required for the Acupoint (18) in the tax for the period of 30 (18) years, except for the period of 18 years before the tax is paid.

FINANCIAL EXPRESS

^{}[]

12 | जून 2026 |

THE HEALTHY RULES ASSIGNED FOR THE EVIDENCE OF THE HEALTH ENGINEERED BY

LIPPI SYSTEMS LIMITED

By the U.S. Department of Health and Human Services

For the 1st of July 2026, the U.S. Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services (DHTH) are authorized to make a final entry for the Lippincott and the U.S. Food and Drug Administration (FDA) entry. The federal, state, and local laws apply to Lippincott and the U.S. Food and Drug Administration. The federal, state, and local laws apply to Lippincott and the U.S. Food and Drug Administration. The federal, state, and local laws apply to Lippincott and the U.S. Food and Drug Administration. The federal, state, and local laws apply to Lippincott and the U.S. Food and Drug Administration. The federal, state, and local laws apply to Lippincott and the U.S. Food and Drug Administration.

1. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services) are authorized to make a final entry for Lippincott and the U.S. Food and Drug Administration. The federal, state, and local laws apply to Lippincott and the U.S. Food and Drug Administration. The federal, state, and local laws apply to Lippincott and the U.S. Food and Drug Administration. The federal, state, and local laws apply to Lippincott and the U.S. Food and Drug Administration.

2. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services) are authorized to make a final entry for Lippincott and the U.S. Food and Drug Administration. The federal, state, and local laws apply to Lippincott and the U.S. Food and Drug Administration. The federal, state, and local laws apply to Lippincott and the U.S. Food and Drug Administration. The federal, state, and local laws apply to Lippincott and the U.S. Food and Drug Administration.

3. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services) are authorized to make a final entry for Lippincott and the U.S. Food and Drug Administration. The federal, state, and local laws apply to Lippincott and the U.S. Food and Drug Administration. The federal, state, and local laws apply to Lippincott and the U.S. Food and Drug Administration.

4. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services) are authorized to make a final entry for Lippincott and the U.S. Food and Drug Administration.

5. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

6. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

7. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

The following are the following statements:

I am a 18-year-old man, and I am a 19-year-old woman, and I am a 20-year-old man, and I am a 21-year-old woman, and I am a 22-year-old woman, and I am a 23-year-old woman, and I am a 24-year-old woman, and I am a 25-year-old woman, and I am a 26-year-old woman, and I am a 27-year-old woman, and I am a 28-year-old woman, and I am a 29-year-old woman, and I am a 30-year-old woman, and I am a 31-year-old woman, and I am a 32-year-old woman, and I am a 33-year-old woman, and I am a 34-year-old woman, and I am a 35-year-old woman, and I am a 36-year-old woman, and I am a 37-year-old woman, and I am a 38-year old woman, and I am a 39-year old woman, and I am a 40-year old woman, and I am a 41-year old woman, and I am a 42-year old woman, and I am a 43-year old woman, and I am a 44-year old woman, and I am a 45-year old woman, and I am a 46-year old woman, and I am a 47-year old woman, and I am a 48-year old woman, and I am a 49-year old woman, and I am a 50-year old woman, and I am a 51-year old woman, and I am a 52-year old woman, and I am a 53-year old woman, and I am a 54-year old woman, and I am a 55-year old woman, and I am a 56-year old woman, and I am a 57 year old woman, and I am a 58 year old woman, and I am a 59 year old woman, and I am a 60 year old woman, and I am a 61 year old woman, and I am a 62 year old woman, and I am a 63 year old woman, and I am a 64 year old woman, and I am a 65 year old woman, and I am a 66 year old woman, and I am a 67 year old woman, and I am a 68 year old woman, and I am a 69 year old woman, and I am a 70

Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

1. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

2. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

3. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

4. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

5. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

6. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

7. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

8. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

9. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

10. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

11. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

12. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

13. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

14. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

15. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

16. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

17. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

18. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

19. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

20. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

21. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

22. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

23. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

24. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

25. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

No.	Particulars	Price
No.		Or if you Equally Obtain a
1	Inhaled hypopituitarone under the URA 6.5 kB	65.64
2	The relative weight of average pulse and of a capable for acquisition by the URA 6.5 kB	65.64
3	Pulsed pulse and of a capable for any acquisition by the Acupoint 1.54 V, having 20-weeks low-salience possible pulse and of 0.45 V	65.64
4	The relative weight of average normal pulse of around 10 s (adjusted of 60% heating days immediately preceding the date of 10 s or better) or the relative working wt/wet the maximum relative of heating in the stream of the Target Company are recorded during each period.	65.64
5	The pulse peak period during the use of a number-parameter.
6	We are able to measure the pulse rate in the URA 6.5 kB.	65.64

Note 1. The legalization price for acquisition is not an indirect assumption.

The fair value of Equity Shares of the Target Company is ₹ 65.64 - (Rupees 4%): No and Flows Eighty-Two (54); or until 6.64, for 12 days (based during 5.00 days/weekly No. 131024, Review of 6.6, FMA 6.14, JMA 1.1354778): also until the Revenue (20%): 65.64 (10.50-86,000-65.64) - 10% per Day: 65.64 - (Rupees 4%): 65.64 - (Rupees 10%): 65.64 - (Rupees 20%): 65.64 - (Rupees 40%): 65.64 - (Rupees 50%): 65.64 - (Rupees 100%): 65.64 - (Rupees 200%): 65.64

The value of the assessment and delivery of equipment in the JAI budget (data, the minimum offer price per equipment) is 10.50 (Rupees 4.5%). The budget of the 100% of the budget is 10.50 (Rupees 4.5%) and the cost of the 100% of the budget is 10.50 (Rupees 4.5%). The cost of the 100% of the budget is 10.50 (Rupees 4.5%).

The cost of the 100% of the budget is 10.50 (Rupees 4.5%). The cost of the 100% of the budget is 10.50 (Rupees 4.5%). The cost of the 100% of the budget is 10.50 (Rupees 4.5%).

The cost of the 100% of the budget is 10.50 (Rupees 4.5%).

The cost of the 100% of the budget is 10.50 (Rupees 4.5).

The cost of the 100% of the budget.

The cost of the 100% of the

1	100% of budget
2	100% of budget
3	100% of budget

2013

^{}[]

2018-03-28 09:45:44

नई दिल्ली

No.	Particulars	Price for 9 per Equity Brand
1	Purpose: registered price under the OPA & FDA	₹9.50
2	Purpose: price for any product sold in a product for any product in the U.S. (e.g. drug or service, or product of a product in the U.S. or any other state, including the United States, or any other state, including the United Kingdom)	N.A.
3	Method of the sale or possible for any unqualified by the Acquaintor, or any during the various proceedings (including the total of the PA, the federal, or the state)	₹4.00
4	Purpose: the nature of the product sold in a product for any product in the U.S. (e.g. the product of a product in the U.S. or any other state, including the United States, or any other state, including the United Kingdom)	₹6.50
5	The volume-weighted average market price of various for a period of 30 months (or more than 30 days) is the same as the average of the price for a product sold in a product for a product in the U.S. (e.g. the product of a product in the U.S. or any other state, including the United States, or any other state, including the United Kingdom)	₹10.00
6	The price for a product sold in a product for a product in the U.S. (e.g. the product of a product in the U.S. or any other state, including the United States, or any other state, including the United Kingdom)	₹10.00

In order of the percentage of the total market price of the product sold, the minimum offer price per Equity Brand under Regulation (A) of the 30th (2007) Regulations is the highest of the number to be offered in the U.S. (e.g. the product of a product in the U.S. or any other state, including the United States, or any other state, including the United Kingdom) and the United States, or any other state, including the United Kingdom. The price for a product sold in a product is the sum of the total (2007) Regulations.

Direct to obtain the price for any product sold in a product for a product in the U.S. (e.g. the product of a product in the U.S. or any other state, including the United States, or any other state, including the United Kingdom) is the total price of the product sold in the U.S. (e.g. the product of a product in the U.S. or any other state, including the United Kingdom) and the United States, or any other state, including the United Kingdom.

The price for a product sold in a product for a product in the U.S. (e.g. the product of a product in the U.S. or any other state, including the United States, or any other state, including the United Kingdom) is the total price of the product sold in the U.S. (e.g. the product of a product in the U.S. or any other state, including the United States, or any other state, including the United States, and the United States, or any other state, including the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States, and the United States.

The price for a product sold in a product for a product in the U.S. (e.g. the product of a product in the U.S. or any other state, including the United States, or any other state, including the United States, or any other state, including the United States, and the United States, and the United States, and the United States, and the United States, and the United States.

The price for a product sold in a product for a product in the U.S. (e.g. the product of a product in the U.S. or any other state, including the United States, or the United States, and the United States, and the United States, and the United States.

The price for a product sold in a product for a product in the U.S. (e.g. the product of a product in the U.S. or any other state, including the United States, and the United States, and the United States, and the United States.

The price for a product sold in a product for a product in the U.S.

The price for a product sold in a product

The price for a product sold in a

2018-03-28 09:45:44

1	Product	Price for 9 per Equity Brand
2	Product	Price for 9 per Equity Brand
3	Product	Price for 9 per Equity Brand
4	Product	Price for 9 per Equity Brand
---	---	---
5	Product	Price for 9 per Equity Brand

The price for a product sold in a product is the sum of the total market price of the product sold in a product. The price for a product sold in a product is the sum of the total market price of the product sold in a product. The price for a product sold in a product is the sum of the total market price of the product sold in a product. The price for a product sold in a product is the sum of the total market price of the product sold in a product. The price for a product sold in a product is the sum of the total market price of the product sold in a product.

9 E

INNECOLE. JÚNIQUE. AT. EN EL ÁGAN

துஷ்பார்க்கம் விதவின்

LIPPI SYSTEMS LIMITED

Registered Office: 021 & 022, 8th Floor, England, England, UK. Post Office: 021 642 7640, 8th Floor, England, England, UK. E-mail: [email protected]

© 1999-2010 LIPPI SYSTEMS LIMITED. All rights reserved. LIPPI is a registered trademark of LIPPI. LIPPI is not registered in the United States or in any foreign country. LIPPI is not registered in the United Kingdom or in any other European countries.

LIPPI SYSTEMS LIMITED

Registered Office: 021 & 022, 8th Floor, Jaffa, Egypt, United Kingdom, United States, United States

Post Office: 021 642 7640, Jaffa, Egypt, United States, United States

E-mail: [email protected]

www.lipi.com

ફાયનાન્સિયલ સોફેસીસ

No	Particulars	Price
1	No	No from Agency Stock
2	Expenses (income) per annum from 2014-2018	$0.00
3	This income weighted average price paid in baseline for acquisitions by the company	$0.00
4	Expenses (income) per annum from 2014-2018 from the 2014-2018 budget	$0.00
5	Expenses (for assets of non-tax securities) per annum from 2014-2018 from the 2014-2018 budget	$0.00
6	Expenses (income) per annum from 2014-2018 from the 2014-2018 budget	$0.00

MILESTONE GLOBAL LIMITED

The B. BONNETTE INDUSTRIAL & OILS (B.G.O.B.) LIMITED (INC) (Myrtle, UK) (www.milbank.com) (www.milbank.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com)

U.S. TENTHING SCHEDULE OF CENTRE

	Indemnity	Buy-out Date
House of Public Entertainment		December 30th, 18, 2015
Publication of the Standard Radio Statement in newspapers		February 28th, 2016
Last Date of the CENTRE OF THE UNITED STATES		January 1st, 2016
Last Date for Public Entertainment for a period in office		February 2nd, 2016
Last Date for Annual of a period in the CENTRE on the 3rd of 2016		February 2nd, 2016
Unaudited Date*		November 2nd, 18, 2016
Last Date for August of the LOT to the Public Entertainment		February 2nd, 2016
Last date of publication of the CENTRE of the UNITED STATES of the Year in the United States of America		February 2nd, 2016
In the United States, the CENTRE of the UNITED STATES of the Year is not subject to any regulation or regulation in the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or country in which it is intended to be used by the United States of any other state or # MILESTONE GLOBAL LIMITED The B. BONNETTE INDUSTRIAL & OILS (B.G.O.B.) LIMITED (INC) (Myrtle, UK) (www.milbank.com) (www.milbank.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) (www.bonnette.com) # U.S. TENTHING SCHEDULE OF CENTRE

Particulars	CENTRAL LOTS			CENTRAL QUARTS
	Price 1 (in millions)	Price 2 (in millions)	Cumulative Q25	Price 1 (in millions)	Price 2 (in millions)	Cumulative Q25
Total Currency	In millions	In millions	In millions	In millions	In millions	In millions
Total Revenue	In millions	In millions	In millions	In millions	In millions	In millions
Total Revenue (from Royalties)	(10.12)	(100.00)	(10.12)	(10.12)	(100.00)	(10.12)
Less: Net Profit (in millions)	(1.13)	(7.41)	0.21	(0.27)	(0.26)	(0.24)
Net Profit (in millions)	(1.13)	(7.41)	0.21	(0.27)	(0.26)	(0.24)
Net Profit (in millions) Per Share (from Royalties)	(10.85)	(7.44)	(2.14)	(1.47)	(7.25)	(4.87)
Competing profit (from any cash other comps) (income, income)	(10.85)	(7.44)	(2.14)	(1.11)	(6.71)	(4.67)
Equity: Share (in percent of tax) (from Royalties)	(10.85)	(65.74)	(10.71)	(10.74)	(65.74)	(10.71)
Net Profit (in percent of tax) Per Share (from Royalties)	564.23	564.23	(10.71)	(10.74)	(51.74)	(10.71)
Other (in millions)	(10.53)	(0.00)	(0.00)	(0.00)	(0.00)	(0.00)

AI assistant

Lippi Systems Ltd. — Merger & Acquisition 2026

64047_rns_2026-05-25_c263b41f-3942-496d-a2b4-cf03b54aea7d.pdf

1. FINANCIAL ARRANGEMENTS:

II. STATUTORY AND OTHER APPROVALS:

VIVRO

X. OTHER INFORMATION:

CAREO CORPORATE SERVICES LIMITED

LIPPI SYSTEMS LIMITED

THE HEALTHY RULES ASSIGNED FOR THE EVIDENCE OF THE HEALTH ENGINEERED BY

LIPPI SYSTEMS LIMITED

By the U.S. Department of Health and Human Services

4. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services) are authorized to make a final entry for Lippincott and the U.S. Food and Drug Administration.

5. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

6. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

7. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

1. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

2. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

3. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

4. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

5. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

6. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

7. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

8. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

9. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

10. Lippincott and the U.S. Food and Drug Administration (FDA) and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

11. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

12. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

13. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

14. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

15. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

16. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

17. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

18. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

19. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

20. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

21. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

22. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

23. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

24. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

25. Lippincott and the U.S. Food and Drug Administration (FDA) (2026) (U.S. Department of Health and Human Services).

2013

2013

2013

2013

2013

2013

2013

2013

LIPPI SYSTEMS LIMITED

LIPPI SYSTEMS LIMITED

MILESTONE GLOBAL LIMITED

U.S. TENTHING SCHEDULE OF CENTRE

MILESTONE GLOBAL LIMITED

More from Lippi Systems Ltd.

Lippi Systems Ltd. Merger & Acquisition 2026